CMR Seminar Series: Dr. Mone Zaidi
- Kalp Patel
- Aug 14
- 3 min read
Dear All,
We are excited to announce that we will be hosting Dr. Mone Zaidi, Director of the Institute for Translational Medicine & Pharmacology, as our speaker for the Center for Musculoskeletal Research Seminar Series.
Dr. Zaidi will share insights regarding, "Can We Treat Osteoporosis, Obesity, and Alzheimer’s Disease Using a Single FSH-Blocking Therapeutic ?".
Meeting details:
Speaker: Mone Zaidi, MD, PhD
Director of the Institute for Translational Medicine & Pharmacology,
Mount Sinai
Date: 08/14/2026
Time: 12:00 PM Location: Turner G007
Meeting ID: 928 5205 4549
Passcode: 24601
Dr. Mone Zaidi graduated in medicine from King George’s Medical College, India, and trained clinically at the Hammersmith Hospital, London, under the tutelage of Professor Iain MacIntyre, FRS, who discovered calcitonin. After obtaining a PhD and MD from the University of London, Dr. Zaidi held faculty appointments for over 8 years, before he was recruited to Mount Sinai School of Medicine as Professor of Medicine and Founding Director of The Mount Sinai Bone Program. He is currently the Mount Sinai Endowed Professor of Clinical Medicine and Director of the Institute for Translational Medicine and Pharmacology.
Dr. Zaidi has made groundbreaking discoveries on mechanisms of skeletal homeostasis in health and disease. These studies, spanning over 30 years, included the first description of calcium sensing in bone cells and the discovery that locally released nitric oxide acts to suppress bone remodeling. In 2003, Zaidi’s group published the first evidence for a pituitary–bone axis, a breakthrough in physiology in which pituitary hormones could affect the skeleton directly. In two more recent groundbreaking papers in Nature, he found that inhibiting FSH not only increased bone mass but also reduced body fat and prevented neurodegeneration—in essence, laying a firm foundation for Zaidi’s new drug––an anti-FSH agent to treat osteoporosis, obesity and Alzheimer’s disease––that is currently under late–stage development. This corpus of work was selected by Nature Medicine as one of eight “Notable Advances” in biomedicine for 2017 and was editorialized in the New York Times.
Constituting a total of over 500 publications in journals and books, including Cell, Nature and PNAS, Zaidi’s research has been funded continuously by the National Institutes of Health for over 30 years. He was elected to the American Society of Clinical Investigation (2000), Association of American Physicians (2004), Interurban Clinical Club of which he is Past President (2004), the Practitioners’ Society (the oldest medical society in the U.S.) (2016), of which he was elected President, and the Association of Professors of Medicine (2014). Dr. Zaidi was made Master of the American College of Physicians, received the Harrington Scholar–Innovator Award, was elected as Fellow of the American Association of Advancement of Science (AAAS), and of the National Academy of Inventors, won the Austrian International Research Prize and the Special Recognition Award from the Association of Professors of Medicine, was bestowed upon with an Honorary Fellowship by the British Pharmacological Society, and is recipient of five honorary doctorates. He was the 2023 Commencement Speaker at the University of Connecticut and was elected as a Foreign Member of the European Academy of Sciences and Academia Europaea. More recently, Zaidi has been awarded the 2024 Hariett P. Dunstan Prize for “outstanding contributions to science related to medicine” given by the American College of Physicians, and the 2025 William F. Neuman Award, the highest recognition bestowed by the American Society for Bone and Mineral Research, as well as, more recently, the Jacobi Medal, the highest honor from Mount Sinai.